Abstract: In the ever-evolving cyber era, cyberattack threats are increasingly diverse and elusive. Precise and complete information related to cyber attacks can be utilised to create a reliable ...
Ocular Therapeutix Inc. (NASDAQ: OCUL) shares are down during Tuesday's premarket session following a significant announcement regarding their Axpaxli treatment for wet age-related macular ...
BEDFORD, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today ...
Bristol Myers Squibb is securing an opportunity to compete in the next generation of cell therapies through the $1.5 billion acquisition of Orbital Therapeutics, a startup with a lead program nearing ...
Oct 10 (Reuters) - Drugmaker Bristol Myers Squibb (BMY.N), opens new tab said on Friday it will acquire privately held cell therapy developer Orbital Therapeutics for $1.5 billion in cash, aiming to ...
Bristol Myers Squibb has agreed to buy privately held biotechnology company Orbital Therapeutics for $1.5 billion in cash in a deal that bolsters the drugmaker's cell-therapy portfolio. Bristol Myers ...
Bristol Myers Squibb (NYSE:BMY) has agreed to acquire privately held biotechnology company Orbital Therapeutics for $1.5 billion in cash. Orbital Therapeutics is advancing a new generation of RNA ...
Drugmaker Bristol-Myers Squibb said on Friday it will acquire privately held cell therapy developer Orbital Therapeutics for $1.5 billion in cash, aiming to diversify from legacy products facing ...
FILE PHOTO: A sign stands outside a Bristol Myers Squibb facility in Cambridge, Massachusetts, U.S., May 20, 2021. REUTERS/Brian Snyder/File Photo (Reuters) -Drugmaker Bristol Myers Squibb said on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results